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Analysis of the complete genome revealed 92% similar-
ity between the 2 isolates, and some genes confirm a remark-
able variability (online Technical Appendix Figure, panel C). 
We constructed a phylogenetic tree (online Technical Appen-
dix Figure, panel D) using the A56R gene sequence by the 
maximum-likelihood method and 1,000 bootstrap replicates 
in MEGA 6.02 (http://www.megasoftware.net). The analysis 
demonstrated a co-infection with viruses from both VACV-BR 
groups, such that the large-plaque clone clustered with group 2 
VACV-BR isolates and the small-plaque clone clustered with 
group 1 VACV-BR isolates. We named these isolates Caran-
gola eye virus 1 (small) and Carangola eye virus 2 (large).
Our study demonstrated the genetic and phenotypic vari-
ability between 2 viruses isolated from the same sample in a 
natural human co-infection with VACV. The viruses belong 
to 2 distinct VACV-BR groups, reinforcing and expanding 
previous work with other hosts (6–8). These results raise new 
questions about how co-infections with these viruses might 
change the aspects of an infection and its signs and symp-
toms, such as development of ocular vaccinia. Although cas-
es of ocular vaccinia have been reported after vaccination and 
accidental laboratory infection (9,10), we proved the associa-
tion and isolate VACV samples from a natural ocular vaccinia 
infection. The effort to understand singular aspects of VACV-
BR co-infections should be increased, and further molecular 
and biologic characterizations of these samples should be 
conducted to identify and better understand the natural dy-
namics and signs and symptoms caused by VACV-BR.
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Primary amebic meningoencephalitis is an acute, rare, typi-
cally fatal disease. We used epidemiologic risk factors and 
multiple cause-of-death mortality data to estimate the num-
ber of deaths that fit the typical pattern for primary amebic 
meningoencephalitis; we estimated an annual average of 
16 deaths (8 male, 8 female) in the United States.
1Preliminary results of this study were presented at the Infectious 
Diseases Society of America Conference; October 8–12, 2014, 
Philadelphia, Pennsylvania, USA.
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Naegleria fowleri causes primary amebic menin-goencephalitis (PAM); 0–8 laboratory-confirmed 
cases per year are documented in the United States) (1). 
PAM causes <0.5% of diagnosed encephalitis deaths in 
the United States (2). Laboratory-confirmed PAM case-
patients in the United States are a median age of 12 years 
and are identified primarily in southern states during 
July–September, and 79% are male (1,3). Many case-pa-
tients are identified postmortem; 4 known survivors have 
been reported in the United States (1,4). The signs and 
symptoms of PAM can be mistaken for other more com-
mon neuroinfections, such as bacterial meningitis and vi-
ral encephalitis (1,4). Because more than half of neuroin-
fectious deaths are unspecified (2), clinical expertise and 
diagnostic testing availability are limited, and true PAM 
incidence is unknown, concern is reasonable that PAM 
cases might not be diagnosed. In this study, we estimate 
the magnitude of potentially undiagnosed cases of PAM 
by applying previously identified epidemiologic risk fac-
tors to unspecified neuroinfectious deaths.
We created a list of codes from the International 
Classification of Disease, 10th revision (ICD-10), for un-
specified possible neuroinfectious deaths by using previ-
ously published data (2), ICD-10 codes from death certif-
icates of known PAM case-patients, and expert opinion. 
We selected codes from any location on the death record, 
not strictly the primary or immediate cause of death 
(http://www.cdc.gov/nchs/deaths.htm). We chose to start 
in 1999 when death certificate data were first coded by 
using ICD-10 and ended in 2010, using the most updated 
data at the time of this analysis. Persons 2–22 years of 
age were included (±10 years from the average age of 12 
years), excluding infants and older adults, who are more 
susceptible to bacterial meningitis. We applied known 
risk factors for PAM: 1) geographic location, i.e., states 
that reported diagnosed cases as of 2010; 2) summer sea-
sons; and 3) sex (3). Within this narrowed subset of un-
specified neuroinfectious deaths, we reviewed associated 
ICD-10 codes and removed death records that had more 
definitive diagnoses.
During 1999–2010, there were 1,676 unspecified neu-
roinfectious disease deaths among persons 2–22 years old; 
49% (826/1,676) occurred during July–September of each 
year studied, and of those, 23% (192/826) were reported 
from an included state in the southern United States; 52% 
(100/192) were male and 48% (92/192) female. An average 
of 16 (8 male, 8 female) unspecified neuroinfectious deaths 
per year fit the typical pattern of PAM, in addition to the 
average 3 laboratory-confirmed cases annually during this 
time period. 
Among all unspecified neuroinfectious deaths, the 
most common unspecified neuroinfectious death code used 
was G03.9 meningitis unspecified (n = 505) (Table). For 
the top 5 codes, 8%–16% of cases matched all the risk 
factors and 2 had a sex ratio of exactly 50%. We did not 
have access to death certificates for 20 known laboratory- 
confirmed case-patients to determine what ICD-10 codes 
were used in these cases.
Our estimate of annual undiagnosed PAM cases 
shows that unspecified neuroinfectious deaths that fit 
the epidemiologic pattern of PAM occur infrequently. 
This estimate likely includes unspecified neuroinfec-
tious death caused by other pathogens. We have no 
method to differentiate cases that fit the pattern of PAM, 
but are caused by another pathogen. Bacterial meningi-
tis, which can be mistaken for PAM (1), has decreased 
over approximately the same time period as this study, 
but does not have the epidemiologic pattern of PAM 
 
Table. Unspecified neuroinfectious death ICD-10 codes by epidemiologic risk factor for primary amebic meningoencephalitis among 
persons 2–22 years of age, United States, 1999–2010*† 
ICD-10 code, disease Total 
In high-incidence 
states‡ (%) July–Sept (%) 
In high-incidence states,‡ July–Sept 
Male patients (%) Female patients (%) 
G03.9, Meningitis unspecified 505 257 (51) 96 (19) 28 (6) 28 (6) 
G04.9, Encephalitis, myelitis and 
encephalomyelitis, unspecified 
479 222 (46) 135 (28) 33 (7) 26 (5) 
R29.8, Other and unspecified symptoms and 
signs involving the nervous and 
musculoskeletal systems 
264 112 (42) 63 (24) 8 (3) 13 (5) 
G00.9, Bacterial meningitis, unspecified 222 105 (47) 41 (18) 11 (5) 11 (5) 
A86, Unspecified viral encephalitis 154 92 (60) 40 (26) 15 (10) 9 (6) 
G06.2, Extradural and subdural abscess, 
unspecified 
59 31 (53) 12 (20) 4 (7) 0 
A87.9, Viral meningitis, unspecified 38 25 (66) 13 (34) 4 (11) 4 (11) 
A89, Unspecified viral infection of the central 
nervous system 
6 2 (33) 3 (50) 0 1 (17) 
A83.9, Mosquito-borne viral encephalitis, 
unspecified 
1 1 (100) 1 (100) 0 1 (100) 
*Codes without cases (R83.5, A92.9, A85.2, A84.9, A81.9, A94, A06.6) not listed. ICD-10, International Classification of Disease, 10th revision. 
†The total provided is greater than the total number of cases because each case may have >1 ICD-10 code. 
‡Arizona, Arkansas, California, Florida, Georgia, Louisiana, Mississippi, Missouri, Nevada, New Mexico, North Carolina, Oklahoma, South Carolina, 
Texas, and Virginia. 
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(5). Viral causes (i.e., La Crosse and West Nile viruses) 
have a similar pattern, occurring during July–Septem-
ber (>80% of cases) and more commonly in males (3:2 
male:female ratio) (6). An ICD-10 code for West Nile 
virus, A92.3, was added in 2005. There was only 1 case 
in our estimate that had the code Mosquito-borne viral 
encephalitis, unspecified (A83.9). Similar to PAM, cases 
of arbovirus disease could be included in even less-spe-
cific meningitis and encephalitis codes, illustrating that 
unspecified neuroinfectious deaths are likely caused by 
several pathogens.
Medical chart review and autopsies, not available for 
this study, would provide further information about the 
cause of death. Although this estimate  likely captures more 
than just PAM cases for the reasons we have outlined, it 
might not capture all potential PAM cases. Reasons for an 
underestimate include inaccurate ICD-10 coding (7) and 
PAM cases that are outside the typical epidemiologic pat-
tern (e.g., 2 cases in Minnesota [(8)] and out of season, 
such as adult cases linked to ritual nasal rinsing and sinus 
irrigation [(9,10)].
Although all available evidence points to PAM being 
a low-incidence disease in the United States, PAM remains 
a devastating and nearly universally fatal infection that 
erodes public confidence in the safety of everyday activi-
ties (swimming, using public drinking water) and increased 
stress on local public health departments that are already 
overextended. The reports of recent survivors indicate that 
timely diagnosis and early initiation of anti-amebic therapy 
may be instrumental in combating this deadly infection (4). 
Therefore awareness, evaluation of risk factors, testing, 
and early anti-amebic therapy provide the best opportunity 
for survival (1).
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